Biomarkers of acute and chronic pancreatitis

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Pancreatitis and pancreatic cancers are very serious diseases with very poor prognosis, and many patients die before even reaching the clinical stage. Therefore, identification of reliable and specific biomarkers at early stages of pancreatitis and pancreatic cancers could be the key to their early prevention and therapy. In this chapter, currently used and putative biomarkers of acute and chronic pancreatitis are summarized. Serum total amylase and lipase in combination or individually remain the most widely used biomarkers for clinical diagnostics of acute pancreatitis. Definitely, lipase assay has an advantage over amylase in clinical diagnostics of acute pancreatitis rather than chronic pancreatitis and appears to have greater specificity. However, imaging technologies strongly support the diagnosis of both acute and chronic pancreatitis. Identification and development of biomarkers of chronic pancreatitis remain challenging because of the impaired secretory component of the exocrine pancreas due to slow destruction of the gland during chronic pancreatitis, particularly at later stages. Therefore, the focus of future research lies in identification of molecular biomarkers by utilizing proteomic, metabolomic, and microRNA array technologies in well-defined experimental models followed by their confirmation in large cohorts of patient populations with acute and various stages of chronic pancreatitis.

Original languageEnglish (US)
Title of host publicationBiomarkers in Toxicology
PublisherElsevier Inc.
Pages279-289
Number of pages11
ISBN (Print)9780124046306
DOIs
StatePublished - Mar 2014

Fingerprint

Chronic Pancreatitis
Biomarkers
Pancreatitis
Amylases
Lipase
Pancreatic Neoplasms
Secretory Component
Technology
Exocrine Pancreas
Metabolomics
Secondary Prevention
MicroRNAs
Proteomics
Theoretical Models
Serum
Population

Keywords

  • Acute pancreatitis
  • Chronic pancreatitis
  • Diagnostic biomarkers
  • Functional biomarkers
  • Pancreatic cancer

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Biomarkers of acute and chronic pancreatitis. / Kaphalia, Bhupendra.

Biomarkers in Toxicology. Elsevier Inc., 2014. p. 279-289.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kaphalia, Bhupendra. / Biomarkers of acute and chronic pancreatitis. Biomarkers in Toxicology. Elsevier Inc., 2014. pp. 279-289
@inbook{580ea8cdd58e483a9f51b0b89d06c3c8,
title = "Biomarkers of acute and chronic pancreatitis",
abstract = "Pancreatitis and pancreatic cancers are very serious diseases with very poor prognosis, and many patients die before even reaching the clinical stage. Therefore, identification of reliable and specific biomarkers at early stages of pancreatitis and pancreatic cancers could be the key to their early prevention and therapy. In this chapter, currently used and putative biomarkers of acute and chronic pancreatitis are summarized. Serum total amylase and lipase in combination or individually remain the most widely used biomarkers for clinical diagnostics of acute pancreatitis. Definitely, lipase assay has an advantage over amylase in clinical diagnostics of acute pancreatitis rather than chronic pancreatitis and appears to have greater specificity. However, imaging technologies strongly support the diagnosis of both acute and chronic pancreatitis. Identification and development of biomarkers of chronic pancreatitis remain challenging because of the impaired secretory component of the exocrine pancreas due to slow destruction of the gland during chronic pancreatitis, particularly at later stages. Therefore, the focus of future research lies in identification of molecular biomarkers by utilizing proteomic, metabolomic, and microRNA array technologies in well-defined experimental models followed by their confirmation in large cohorts of patient populations with acute and various stages of chronic pancreatitis.",
keywords = "Acute pancreatitis, Chronic pancreatitis, Diagnostic biomarkers, Functional biomarkers, Pancreatic cancer",
author = "Bhupendra Kaphalia",
year = "2014",
month = "3",
doi = "10.1016/B978-0-12-404630-6.00016-6",
language = "English (US)",
isbn = "9780124046306",
pages = "279--289",
booktitle = "Biomarkers in Toxicology",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Biomarkers of acute and chronic pancreatitis

AU - Kaphalia, Bhupendra

PY - 2014/3

Y1 - 2014/3

N2 - Pancreatitis and pancreatic cancers are very serious diseases with very poor prognosis, and many patients die before even reaching the clinical stage. Therefore, identification of reliable and specific biomarkers at early stages of pancreatitis and pancreatic cancers could be the key to their early prevention and therapy. In this chapter, currently used and putative biomarkers of acute and chronic pancreatitis are summarized. Serum total amylase and lipase in combination or individually remain the most widely used biomarkers for clinical diagnostics of acute pancreatitis. Definitely, lipase assay has an advantage over amylase in clinical diagnostics of acute pancreatitis rather than chronic pancreatitis and appears to have greater specificity. However, imaging technologies strongly support the diagnosis of both acute and chronic pancreatitis. Identification and development of biomarkers of chronic pancreatitis remain challenging because of the impaired secretory component of the exocrine pancreas due to slow destruction of the gland during chronic pancreatitis, particularly at later stages. Therefore, the focus of future research lies in identification of molecular biomarkers by utilizing proteomic, metabolomic, and microRNA array technologies in well-defined experimental models followed by their confirmation in large cohorts of patient populations with acute and various stages of chronic pancreatitis.

AB - Pancreatitis and pancreatic cancers are very serious diseases with very poor prognosis, and many patients die before even reaching the clinical stage. Therefore, identification of reliable and specific biomarkers at early stages of pancreatitis and pancreatic cancers could be the key to their early prevention and therapy. In this chapter, currently used and putative biomarkers of acute and chronic pancreatitis are summarized. Serum total amylase and lipase in combination or individually remain the most widely used biomarkers for clinical diagnostics of acute pancreatitis. Definitely, lipase assay has an advantage over amylase in clinical diagnostics of acute pancreatitis rather than chronic pancreatitis and appears to have greater specificity. However, imaging technologies strongly support the diagnosis of both acute and chronic pancreatitis. Identification and development of biomarkers of chronic pancreatitis remain challenging because of the impaired secretory component of the exocrine pancreas due to slow destruction of the gland during chronic pancreatitis, particularly at later stages. Therefore, the focus of future research lies in identification of molecular biomarkers by utilizing proteomic, metabolomic, and microRNA array technologies in well-defined experimental models followed by their confirmation in large cohorts of patient populations with acute and various stages of chronic pancreatitis.

KW - Acute pancreatitis

KW - Chronic pancreatitis

KW - Diagnostic biomarkers

KW - Functional biomarkers

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84902223309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902223309&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-404630-6.00016-6

DO - 10.1016/B978-0-12-404630-6.00016-6

M3 - Chapter

SN - 9780124046306

SP - 279

EP - 289

BT - Biomarkers in Toxicology

PB - Elsevier Inc.

ER -